Metropolis Acquires Ambika Pathology To Boost Maharashtra Presence

19 Sep 2025 CW Team

Established in 1995 by Dr Rajendra Sadashiv Patil, Ambika Pathology is one of the leading diagnostic providers in the region. It operates a central laboratory supported by 12 patient touchpoints and offers a wide range of tests. Nearly 75 per cent of its revenue comes from walk-in B2C patients, reflecting its strong trust among patients and clinicians in Kolhapur and neighbouring towns.

The acquisition forms part of Metropolis’ “String of Pearls” strategy, which focuses on building regional clusters and improving access to advanced diagnostics across India. The Kolhapur facility will strengthen the company’s Western Maharashtra network, where it already operates 19 laboratories across Pune, Sangli, Satara, Solapur, Nashik, Ahmednagar and Kolhapur, supported by over 200 patient service centres and a growing franchise base.

Ameera Shah, Promoter and Executive Chairperson of Metropolis, said: “Maharashtra contributes nearly 40 per cent of our revenues, making it a key growth market. Ambika Pathology strengthens our regional presence and supports our ambition to make high-quality diagnostics accessible to more communities.”

Surendran Chemmenkotil, Managing Director of Metropolis, added: “Kolhapur is a critical healthcare hub. Ambika Pathology will be developed into a mini regional reference lab, enhancing our specialised diagnostics capabilities and enabling better outcomes through operational excellence and digital innovation.”

Dr Rajendra Patil, Founder of Ambika Pathology, commented: “Joining Metropolis brings global standards of science and technology to our region. This collaboration will widen the scope of specialised tests and create new opportunities for patients and professionals in Western Maharashtra.”

Metropolis Healthcare Limited (NSE: METROPOLIS | BSE: 542650), India’s second-largest pathology laboratory chain led by Ameera Shah, has completed its fourth acquisition in the past 10 months with the addition of Dr R.S. Patil’s Ambika Pathology Laboratory in Kolhapur. The NABL-accredited facility has joined the Metropolis network through a Business Transfer Agreement.Established in 1995 by Dr Rajendra Sadashiv Patil, Ambika Pathology is one of the leading diagnostic providers in the region. It operates a central laboratory supported by 12 patient touchpoints and offers a wide range of tests. Nearly 75 per cent of its revenue comes from walk-in B2C patients, reflecting its strong trust among patients and clinicians in Kolhapur and neighbouring towns.The acquisition forms part of Metropolis’ “String of Pearls” strategy, which focuses on building regional clusters and improving access to advanced diagnostics across India. The Kolhapur facility will strengthen the company’s Western Maharashtra network, where it already operates 19 laboratories across Pune, Sangli, Satara, Solapur, Nashik, Ahmednagar and Kolhapur, supported by over 200 patient service centres and a growing franchise base.Ameera Shah, Promoter and Executive Chairperson of Metropolis, said: “Maharashtra contributes nearly 40 per cent of our revenues, making it a key growth market. Ambika Pathology strengthens our regional presence and supports our ambition to make high-quality diagnostics accessible to more communities.”Surendran Chemmenkotil, Managing Director of Metropolis, added: “Kolhapur is a critical healthcare hub. Ambika Pathology will be developed into a mini regional reference lab, enhancing our specialised diagnostics capabilities and enabling better outcomes through operational excellence and digital innovation.”Dr Rajendra Patil, Founder of Ambika Pathology, commented: “Joining Metropolis brings global standards of science and technology to our region. This collaboration will widen the scope of specialised tests and create new opportunities for patients and professionals in Western Maharashtra.”

Equipment

10 Oct 2025

Liebherr Cranes Brave Harsh Seas for Ytre Steinsund Bridge

Four Liebherr high-top cranes are playing a vital role in constructing the Ytre Steinsund Bridge along Norway’s rugged coastline. The cranes’ robust technology and adaptable design are enabling safe and efficient operations despite harsh winds, strong waves, and tight project timelines. The Ytre Steinsund Bridge, now under construction in western Norway, is set to be completed by the end of 2026. Once operational, the cantilever bridge will enhance connectivity between coastal regions near Hardbakke. To meet the project’s demanding conditions along the Sognefjord, the construction team ..

Infrastructure Urban

10 Oct 2025

GREENEXT Expo 2025 Showcases Sustainability as a Business Driver

The GREENEXT Expo 2025 concluded successfully on September 27 at the Shanghai Exhibition Center, reaffirming its status as one of China’s most influential platforms for sustainability transformation. The two-day event positioned sustainability as a tangible business strategy, bringing together over 120 global enterprises and organisations, and attracting 5,022 attendees. Shanghai, September 27, 2025 – The 2025 edition of GREENEXT Expo, China’s leading greening and accelerator platform, focused on the pillars of Sustainability Innovation × Cross-Sector Collaboration × Business. The eve..

Infrastructure Urban

10 Oct 2025

Molecor to Showcase PVC-O Innovation Journey at Upcoming Conference

Molecor, a global leader in Oriented PVC (PVC-O) pipe technology, will host a conference titled “The PVC-O Innovation Journey” on October 10 at 10:30 AM in Room 5 of the CCD South. The session will highlight the company’s latest technological advancements and its continued leadership in sustainable water infrastructure solutions. Molecor invites attendees to explore the latest developments in PVC-O technology during its conference “The PVC-O Innovation Journey”. The event will be led by Ignacio Muñoz, Founder and CEO of Molecor, who will unveil SilkWorm®, the first complete system..